GlassScriptPhysician profile
Diana M Lim
NPI 1023047420
$9,848.85
in general payments reported to CMS, 2019-2025
47 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $1,007 · 2021: $2,022 · 2022: $1,628 · 2023: $1,731 · 2024: $1,084 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,042.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,379.69 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $1,343.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $834.68 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $679.33 | 2019-2025 | |
| Lilly USA, LLC | $634.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $508.71 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $478.76 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Daiichi Sankyo INC. | $325.08 | 2019-2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $279.78 | 2019-2023 | Livalo, Seglentis |
| Astellas Pharma US INC | $271.84 | 2019-2025 | Veozah |
| Abbott Laboratories | $255.52 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $243.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $235.94 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.69 | 2020-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $189.37 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.